The global psychedelics industry is expected to be worth over US$100 billion with the potential to save $1 trillion on lost productivity, disrupting the way we approach healthcare. As attitudes towards psychedelics shift dramatically, we are witnessing an international rise in clinical trials, academic research and commercial investment. The use of psychedelics as medicine is set to open up a new industry at pace. We help investors, operators and regulators navigate the many opportunities through data, intelligence and networking.
We demystify the legislative and regulatory environment surrounding a variety of psychedelics, helping our clients to navigate the changing landscape of each region.
We provide market forecasts and estimates for potential savings to society/economy which are likely to result from psychedelic therapies over the next decade.
We identify and analyse emerging trends for individual psychedelic therapies and monitor innovation and developments in this exciting, burgeoning industry.
THE PSYCHEDELICS AS MEDICINE REPORT: SECOND EDITION
DISRUPTING MODERN HEALTHCARE
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. The Psychedelics as Medicine Report: Second Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
The Psychedelics as Medicine Report: Second Edition examines:
Proprietary consumer insights on attitudes, uses and behaviours
Deep dives into the most transformative compounds and companies
Key regulations, transformative trends and commercial opportunities
HIGHLIGHTS AND INSIGHTS
PSYCH: What are the next steps
PSYCH: What Lies Ahead?
The Future of Therapy
PSYCH: Psychedelics for
PSYCH: Lessons Learned from 50 Years of Psychedelic Activism
NEWS & INSIGHT
Professor David Nutt: The Therapeutic Use of Psychedelics
During The PSYCH Symposium in November 2020, Professor David Nutt, chairman of Awakn Life Sciences, founder of Drug Science and the director of neuropsychopharmacology at Imperial College London, delivered a virtual keynote speech on the impact of psychedelic medicines across history and culture before covering the complex and unbridled potential they hold in the treatmentContinue reading
Gwella and the Untapped Opportunity In Functional Mushrooms
A new company straddling both the functional health and psychedelic space with a consumer/retail first approach. Backed by a leading team of scientists, doctors, investors and experts across the wellness space, the company has full service creative, digital marketing, and e-commerce expertise, which is supported by a board with extensive knowledge of developing, marketing andContinue reading
St. Vincent and the Grenadines Launch Psychedelics Initiative
Exclusive: Saint Vincent and the Grenadines announces initiative to permit psychedelic treatment and research The Caribbean nation of Saint Vincent and the Grenadines has launched an initiative to permit and support psychedelic research and wellness. The initiative will begin as a Medicinal Wellness Feasibility Study, which is expected to last 24 to 30 months, andContinue reading
"Despite psilocybin being a Schedule I substance in the US & a Class A substance in the UK — the most restrictive categories — the researchers found that most participants considered psilocybin to be relatively safe compared to the other substances."
During The PSYCH Symposium in November, @ProfDavidNutt, one of the leading figures operating in the psychedelics sector, delivered a keynote speech & presented an overview of the impact and potential of psychedelic medicines for society.
A retired Fireman has said that using psychedelic medicines helped to save his life amid a personal mental health crisis.